Ethos Financial Group’s Lixte Biotechnology Warrants LIXTW Stock Holding History

Ethos Financial Group’s Portfolio LIXTW Stock Details LIXTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-42,105	Closed	-$3K	–	315
2024 Q2	$3K	Buy	+42,105	New	+$2.75K	﹤0.01%	285
2023 Q3	–	Sell	-42,105	Closed	-$3.63K	–	189
2023 Q2	$3.63K	Buy	+42,105	New	+$3.07K	﹤0.01%	150

Other funds holding LIXTW

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Ethos Financial Group's LIXTW Position: Q3 2024 in Review

Ethos Financial Group sold out of Lixte Biotechnology Warrants (LIXTW) in Q3 2024, closing a stake of 42,105 shares — an estimated $3K sold.

Ethos Financial Group first reported a position in LIXTW in Q2 2023 and held it in 2 quarters. The position peaked at $3.63K in Q2 2023. 3 funds tracked by Wall St. Rank hold LIXTW as of Q3 2024.

Ethos Financial Group reported no remaining Lixte Biotechnology Warrants position as of Q3 2024 after selling out during the quarter.
Ethos Financial Group sold 42,105 Lixte Biotechnology Warrants shares in Q3 2024, an estimated $3K.
Ethos Financial Group first reported a position in Lixte Biotechnology Warrants in Q2 2023 and held it in 2 quarters.
Ethos Financial Group's Lixte Biotechnology Warrants position peaked at $3.63K in Q2 2023.
3 funds tracked by Wall St. Rank held Lixte Biotechnology Warrants as of Q3 2024.

Based on Ethos Financial Group's 13F filing for Q3 2024, filed 7 Nov 2024.